Publications

Find at Harvard

June 1999 (Revised June 2000)
Case

Eckerd Corporation

By: Michael E. Porter and John E. Kelleher

Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details

Keywords: Competition; Alignment; Supply and Industry; Retail Industry; Pharmaceutical Industry

June 2003 (Revised May 2006)
Case

Cipla

By: Rohit Deshpande and Laura Winig

The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details

Keywords: Trade; Price; Global Strategy; Health Care and Treatment; Patents; Leadership; Marketing Strategy; Health Industry; South Africa; India

06 Nov 2019
Video

Accelerating Your Career With Business and Science

July 2008 (Revised September 2008)
Case

Recent Developments in the Ranbaxy Case

By: Robert C. Pozen

This brief case describes settlements Indian drug maker Ranbaxy has made with Pfizer and AstraZeneca, as well as Daiichi Kangyo's purchase of a majority shareholding in Ranbaxy in 2008. View Details

Keywords: Mergers and Acquisitions; Patents; Lawsuits and Litigation; Ownership Stake; Pharmaceutical Industry; India

Find at Harvard

2024
Working Paper

Cephalosporins—Fighting Hospital Infections: Case Histories of Transformational Advances

By: Amar Bhidé, Srikant Datar and Katherine Stebbins

This case history describes the development of three generations of cephalosporins – antibiotics that have significantly reduced hospital infections. Specifically, we chronicle how: 1) Early (pre-cephalosporin) antibiotics were developed in the first half of the 20th... View Details

Keywords: Health Care and Treatment; Technological Innovation; Innovation Strategy; Technology Adoption; Collaborative Innovation and Invention; Innovation and Invention; Governing Rules, Regulations, and Reforms

SSRN

Read Now

Video

Dr. Yusuf Hamied

Dr. Yusuf Hamied, Chair of the pioneering Indian generic drugs company Cipla, discusses the timeline and strategies that allowed him to bring affordable HIV/AIDS treatments to market. View Details

August 2008 (Revised September 2008)
Case

The Flaxil Label (B)

This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details

Keywords: Governance; Risk and Uncertainty; Value Creation; Negotiation; Attitudes; Health Care and Treatment; Government Administration; Pharmaceutical Industry; United States

October 2006 (Revised August 2007)
Case

Calloway Laboratory: Pee for Profit

By: Richard G. Hamermesh and David Kiron

Describes the formation and rapid growth of a drug-testing company. The company needs to decide whether to enter the painkiller testing market, in addition to growing its drug treatment center business. View Details

Keywords: For-Profit Firms; Health Care and Treatment; Health Testing and Trials; Growth and Development Strategy; Market Entry and Exit; Health Industry

September 2021 (Revised October 2022)
Supplement

Hester Pharmaceuticals (B): Securing Supply

By: Dante Roscini and John Masko

Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details

Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Health Care and Treatment; Demand and Consumers; Global Range; Globalized Markets and Industries; Pharmaceutical Industry; Italy; China; United States; Germany

March 1993
Supplement

Burroughs Wellcome and AZT (B)

By: Willis M. Emmons III

Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details

Keywords: Ethics; Health Pandemics; Multinational Firms and Management; Price; Crime and Corruption; Risk and Uncertainty; Business Strategy; Business and Community Relations; Business and Government Relations; Business and Shareholder Relations; Pharmaceutical Industry

October 2024
Case

Allurion: Competing in the Age of GLP-1

By: Satish Tadikonda, Rajiv Lal, David Lane and Sarah Sasso

Shantanu Gaur had built Allurion into a formidable business internationally, providing obesity patients with a less invasive option long before GLP-1 drugs became the latest craze. Selling Allurion's medical device across 60+ countries, he awaited FDA approval to bring... View Details

Keywords: Corporate Entrepreneurship; Health Care and Treatment; Global Strategy; Competitive Strategy; Medical Devices and Supplies Industry; Health Industry; United States; United Kingdom; France; India; Brazil; Middle East

01 Oct 2019
News

The bias that can cause catastrophe

November 2010
Supplement

Hikma Pharmaceuticals (B)

By: John A. Quelch

By 2009, Hikma Pharmaceuticals operated 13 manufacturing plants in 8 countries of which 5 were approved by the U.S. Food and Drug Administration. Hikma tracked its sales revenues over the period to show where the largest contributors were from. View Details

Keywords: Strategy; Knowledge Use and Leverage; Sales; Pharmaceutical Industry

04 Sep 2018
First Look

New Research and Ideas, September 4, 2018

'Wonder Drug' That Killed Babies In the early 1960s, a popular drug taken by patients worldwide for a range of maladies was found to cause severe birth defects and other health problems in babies born to mothers who had taken it during a... View Details

Keywords: Dina Gerdeman

September 2020
Case

Minerva 2004: Discovery

By: John R. Wells and Benjamin Weinstock

After nearly five years in operation, Doctor Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Corporation (Minerva), was reflecting on the company’s next steps. In a few short years, she and her small team had managed to develop a nanoparticle process for... View Details

Keywords: Entrepreneurship; Financing and Loans; Strategy; Decision Choices and Conditions; Biotechnology Industry

Awards

Edward Kremers Award of the American Institute of the History of Pharmacy

Winner of the 2006 Edward Kremers Award from the American Institute of the History of Pharmacy for best book published in the previous two years for Pharmacopolitics: Drug Regulation in the United States and Germany (The University of North Carolina Press,... View Details

23 Jun 2015
Video

Innovations Wanted: Beating Brain Disease

07 Dec 2010
First Look

First Look: Dec. 7

case:http://cb.hbsp.harvard.edu/cb/product/711417-PDF-ENG Plavix: Drugs in the Age of Personalized Medicine Richard G. Hamermesh, Mara G. Aspinall, and Rachel GordonHarvard Business School Note 811-001 PIavix, one of the world's best... View Details

Keywords: Sean Silverthorne

May 2021
Case

The SMA Foundation: Steering Therapeutic Research and Development in a Rare Disease

By: Amitabh Chandra, Spencer Lee-Rey and Caroline Marra

This case explores incentives for rare disease drug development by chronicling the role of the Spinal Muscular Atrophy (SMA) Foundation in forming strategic partnerships with the scientific research community and pharmaceutical developers to transform the trajectory... View Details

Keywords: Innovation and Invention; Strategy; Business or Company Management; Society; Health; Public Administration Industry; Health Industry; United States